Faithlore Gardner, MD
Medical Oncology · Cape Coral, FLNPI 1487858973
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Sanofi at 26.5% of the total. Reporting peaked in 2021 at $17,239 and has fallen 75.3% since, to $4,266 in 2025.
Across 1,204 payments — averaging $61.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$20K
- Regeneron Healthcare Solutions, Inc.$18K
- Johnson & Johnson$8K
- Epizyme, Inc.$7K
- Merck$2K
- Seagen Inc.$2K
- plus $17K from 54 others
Across 489 payments — averaging $5727.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.2M
- Astellas Pharma Global Development$446K
- Genentech, Inc.$435K
- Pharmacyclics LLC, An Abbvie Company$302K
- Novartis$120K
- Macrogenics, Inc.$96K
- plus $212K from 5 others
What the payments were for
- Consulting fees$9,27513%
- Speaking & faculty fees$40,80755%
- Travel & lodging$1,0671%
- Food & beverage$22,60531%
- Education$1510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$73,905 in reported general payments places this provider in the 85th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 72 | $1,262,277 |
| PomalystPomalidomide | 24 | $548,821 |
| XpovioSelinexor | 16 | $359,343 |
| ImbruvicaIbrutinib | 22 | $357,365 |
| VenclextaVenetoclax | 42 | $329,091 |
| NinlaroIxazomib Citrate | 24 | $307,322 |
| BrukinsaZanubrutinib | 21 | $290,161 |
| CalquenceAcalabrutinib Maleate | 17 | $262,868 |
| InlytaAxitinib | 13 | $208,878 |
| TagrissoOsimertinib Mesylate | 12 | $202,825 |
| SprycelDasatinib | 19 | $192,171 |
| IbrancePalbociclib | 12 | $189,592 |
| NubeqaDarolutamide | 14 | $187,680 |
| XtandiEnzalutamide | 12 | $173,356 |
| EliquisApixaban | 72 | $53,808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $1,364 | $1,262,27772 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $1,468 | $740,99243 claims |
| AstraZenecaCalquence, Tagrisso | $1,126 | $465,69329 claims |
| PfizerInlyta, Ibrance, Eliquis | $1,525 | $452,27897 claims |
| Karyopharm Therapeutics Inc.Xpovio | $31 | $359,34316 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $54 | $357,36522 claims |
| AbbVieVenclexta | $234 | $329,09142 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $255 | $307,32224 claims |
| Beigene USA, Inc.Brukinsa | $433 | $290,16121 claims |
| BayerNubeqa | $378 | $187,68014 claims |
| Astellas Pharma US IncXtandi | $436 | $173,35612 claims |
| Johnson & JohnsonXarelto | $7,960 | $14,06717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Cape Coral
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
- Judah FriedmanPalm Beach Gardens$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.